Updated on 2025/03/27

写真a

 
Yamamoto Shoichiro
 
Organization
University Hospital Assistant Professor
Title
Assistant Professor
Contact information
メールアドレス
External link

Degree

  • PhD in Medicine ( 2019.3   Ehime University )

Research Interests

  • Lung cancer

  • 呼吸器内科

  • 悪性腫瘍

  • 機械学習

Research Areas

  • Life Science / Respiratory medicine

Professional Memberships

▼display all

Qualification acquired

  • Medical license

Papers

  • Visual Turing test is not sufficient to evaluate the performance of medical generative models. International journal

    Shoichiro Yamamoto, Akinori Higaki

    European radiology experimental   7 ( 1 )   31 - 31   2023.7

    　More details

  • A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. International journal

    Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, Kaname Nosaki, Yasutaka Watanabe, Terufumi Kato, Daisuke Hayakawa, Hiroshi Tanaka, Toshiaki Takahashi, Masahide Oki, Motoko Tachihara, Daichi Fujimoto, Hidetoshi Hayashi, Kakuhiro Yamaguchi, Shoichiro Yamamoto, Eiji Iwama, Koichi Azuma, Kazuo Hasegawa, Nobuyuki Yamamoto, Kazuhiko Nakagawa

    Lung cancer (Amsterdam, Netherlands)   177   44 - 50   2023.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is an established standard treatment option for chemotherapy-naive patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). However, of such patients who have received prior treatment with a first- or second-generation EGFR TKI, only approximately half are eligible for osimertinib therapy because its indication as second-line treatment and beyond is limited to metastatic NSCLC that is positive for the T790M resistance mutation of the EGFR gene. This study was initiated at the request of a dedicated network for patients with lung cancer in Japan. METHODS: We conducted a phase II study to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. The primary end point was response rate (assessed by a central imaging reviewer). RESULTS: From August 2020 to February 2021, 55 patients from 15 institutions were enrolled in the study. The overall response for primary analysis was achieved in 16 patients (29.1 %; 95 % CI, 17.6-42.9), which exceeded the threshold response rate necessary for analysis. Stable disease was found in 16 patients (29.1 %), and progressive disease, in 18 (32.7 %). The median length of progression-free survival (PFS) was 4.07 months (95 % CI 2.10-4.30), and the rate of 12-month PFS was 17.3 %. CONCLUSIONS: Osimertinib demonstrated modest antitumor activity against progressive EGFR T790M-negative disease.

    DOI： 10.1016/j.lungcan.2023.01.011

    Scopus

    PubMed

    researchmap

  • Use of the forced-oscillation technique to estimate spirometry values Reviewed International journal

    Shoichiro Yamamoto, Seigo Miyoshi, Hitoshi Katayama, Mikio Okazaki, Hisayuki Shigematsu, Yoshifumi Sano, Minoru Matsubara, Naohiko Hamaguchi, Takafumi Okura, Jitsuo Higaki

    International Journal of Chronic Obstructive Pulmonary Disease   Volume 12   2859 - 2868   2017.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Informa UK Limited  

    PURPOSE: Spirometry is sometimes difficult to perform in elderly patients and in those with severe respiratory distress. The forced-oscillation technique (FOT) is a simple and noninvasive method of measuring respiratory impedance. The aim of this study was to determine if FOT data reflect spirometric indices. PATIENTS AND METHODS: Patients underwent both FOT and spirometry procedures prior to inclusion in development (n=1,089) and validation (n=552) studies. Multivariate linear regression analysis was performed to identify FOT parameters predictive of vital capacity (VC), forced VC (FVC), and forced expiratory volume in 1 second (FEV1). A regression equation was used to calculate estimated VC, FVC, and FEV1. We then determined whether the estimated data reflected spirometric indices. Agreement between actual and estimated spirometry data was assessed by Bland-Altman analysis. RESULTS: Significant correlations were observed between actual and estimated VC, FVC, and FEV1 values (all r>0.8 and P<0.001). These results were deemed robust by a separate validation study (all r>0.8 and P<0.001). Bias between the actual data and estimated data for VC, FVC, and FEV1 in the development study was 0.007 L (95% limits of agreement [LOA] 0.907 and -0.893 L), -0.064 L (95% LOA 0.843 and -0.971 L), and -0.039 L (95% LOA 0.735 and -0.814 L), respectively. On the other hand, bias between the actual data and estimated data for VC, FVC, and FEV1 in the validation study was -0.201 L (95% LOA 0.62 and -1.022 L), -0.262 L (95% LOA 0.582 and -1.106 L), and -0.174 L (95% LOA 0.576 and -0.923 L), respectively, suggesting that the estimated data in the validation study did not have high accuracy. CONCLUSION: Further studies are needed to generate more accurate regression equations for spirometric indices based on FOT measurements.

    DOI： 10.2147/copd.s143721

    Scopus

    PubMed

    researchmap

  • モストグラフは肺活量、1秒量を予測する

    三好 誠吾, 山本 千恵, 山本 将一郎, 仙波 真由子, 濱田 千鶴, 片山 均, 岡崎 幹生, 重松 久之, 佐野 由文, 大蔵 隆文, 檜垣 實男

    日本呼吸器学会誌   5 ( 増刊 )   289 - 289   2016.3

    　More details

    Language：Japanese   Publisher：(一社)日本呼吸器学会  

    researchmap

  • [Pulmonary non-tuberculous mycobacteriosis complicated with lung cancer].

    Hiroshi Suehisa, Fumio Matsuda, Hiroaki Kawamoto, Tsuyoshi Ueno, Shigeki Sawada, Motohiro Yamashita, Shoichiro Yamamoto, Daijiro Harada, Hiromoto Kitajima, Toshiyuki Kozuki, Naoyuki Nogami, Hiroyuki Takahata

    Kyobu geka. The Japanese journal of thoracic surgery   67 ( 7 )   549 - 52   2014.7

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    A 54-year-old man with pulmonary non-tuberculous mycobacteriosis( pulmonary NTM) who had been treated by antituberculous chemotherapy, developed a new nodule of 1.3 cm in size in the segment 1/2 of the right upper lobe. The cavity of 3.5 cm in size in the segment 6 of the right lower lobe from which Mycobacterium intracellulare was bronchoscopically detected, was suspected to be pulmonary NTM lesion. Since lung cancer was highly suspected by radiological examinations, right upper lobectomy and S6 segmentectomy were performed. Pathological diagnosis for the right upper lobe nodule was adenocarcinoma.

    PubMed

    researchmap

Books

  • がん免疫ペディア : 腫瘍免疫学・がん免疫療法の全てをまるごと理解!

    吉村, 清

    羊土社  2022.3  （ ISBN:9784758121194 ）

    　More details

    Total pages：220p   Language：Japanese  

    CiNii Books

    researchmap

MISC

▼display all

Teaching Experience

  • 呼吸器内科学

    2021 Institution：愛媛大学

    　More details